Biosortia Contract Gives Researchers Access To Natural Product Chemistry For Drug Discovery Efforts

February 22, 2016

COLUMBUS, OHIO --  Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) that gives the institution’s cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.

Leveraging their areas of expertise in the discovery screening of novel natural products, the contract combines Biosortia’s proprietary natural product chemistry and expertise with OSUCCC – James researchers’ proprietary screening assays and drug development capabilities with the goal of identifying new therapeutic indications.

The agreement will give OSUCCC – James researchers access to Biosortia’s proprietary natural product chemistry molecules for the purpose of drug development studies conducted through Ohio State’s Drug Development Institute (DDI).

Created and funded by the OSUCCC – James, and with the help of seven Ohio State colleges and the university’s technology commercialization office, the DDI helps expedite cancer drug development through strategic partnerships within the global pharmaceutical and research/development industries.

"With more than 200 oncologists, each of whom specializes in just one type of cancer, the OSUCCC – James brings extraordinary sub-specialization expertise to the collaboration. We are encouraged to be working with OSUCCC – James and their dedicated researchers as we strive to deliver targeted therapies that will bring better outcomes in the fight against cancer," says Guy Carter, PhD, Biosortia chief scientific officer.

Biosortia Pharmaceuticals, a natural products drug discovery and development company, leverages nature for the discovery of first-in-class small molecules as potential solutions to high priority unmet needs that will positively impact human health. Together with OSUCCC – James, Biosortia will provide access to pre-optimized small molecule chemistry produced by unculturable aquatic microorganisms for anti-cancer drug discovery.

-30-

Media Contacts:

Amanda Harper
OSUCCC – James
614-685-5420
amanda.harper2@osumc.edu

Chad Hummell
Biosortia
614-573-1903
chummell@biosortia.com

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

What’s Next – Improving Upon Perfection

Dr. Caligiuri challenges himself to get better every day and to help the OSUCCC – James improve upon the perfect score it recently received from the NCI. This is the final part of a six-story series.

Navigating DCIS Breast Cancer Treatment Choices: What Women Need to Know

Women with DCIS, an early-stage form of breast cancer, can now better navigate the right treatment choices specifically for her.

The Three Pillars of Leadership

Intelligence, work ethic and being nice to people are the three key components of the Michael Caligiuri, MD, leadership formula. This is part five of a six-story series.